Addex Therapeutics
ADXN | NASDAQ
$3.83
-$0.23 (-5.67%)
At close: Nov 16, 2026, 4:00 PM ET
$3.72
-$0.11 (-2.87%)
After-hours:
Nov 16, 2026, 7:27 PM ET
Addex Therapeutics Company Profile
Company profile explainedCompany Profile
Addex Therapeutics Ltd, a biopharmaceutical firm in a developmental phase, operates out of Switzerland, focusing on the discovery, advancement, and commercialization of small-molecule drugs targeting central nervous system (CNS) disorders. Their core strategy involves identifying oral small-molecule allosteric modulators for G-protein coupled receptors. The company's key programs include Dipraglurant, an investigational treatment for Parkinson's disease levodopa-induced dyskinesia and dystonia; ADX71149, which is being developed for epilepsy and other unspecified CNS conditions; and GABAB PAM, a compound aimed at treating addiction. Addex Therapeutics has established licensing and collaboration agreements with significant partners, including Janssen Pharmaceuticals Inc., Indivior PLC, and The Charcot–Marie–Tooth Association. Founded in 2002 and based in Geneva, Switzerland, the company was initially known as Addex Pharmaceuticals Ltd before officially changing its name to Addex Therapeutics Ltd in March 2012.
Key Executives
| Name | Position |
|---|---|
| Timothy Mark Dyer | Co-Founder, Chief Executive Officer & Director |
| Jean-Philippe Rocher | Head of Pharmaceutical Development & Member of Executive Management |
| Lénaic Teyssédou | Head of Finance |
| Mikhail Kalinichev | Head of Translational Science |
| Roger G. Mills | Chief Medical Officer & Director |
Addex Therapeutics
| Country | Switzerland |
| IPO Date | Feb 12, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 3 |
| CEO | Timothy Mark Dyer |
Contact Details
Chemin des Mines, 9 Geneva,
GE 1202 Switzerland
Stock Details
| Ticker Symbol | ADXN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001574232 |
| CUSIP Number | 00654J206 |
| ISIN Number | US00654J2069 |
| SIC Code | 2834 |
Add to Watchlist
Select watchlists to add or remove ADXN